Found 201 clinical trials
COhort for Bardet-Bield Syndrome and Alstr m Syndrome for Translational Research Monocentric Interventional Study
There are to date no specific treatments available and limited information on the natural history of the diseases. the investigators aim to establish a French cohort for these diseases to improve patient care and assess the effect of actual therapies on quality of life. The purpose of this study is …
- 0 views
- 19 Feb, 2024
The Acute Effects of Pragmatic Manual Therapy on the Range of Motion of Shoulder Joint
Manual intervention should therefore address these issues in conjunction with the other therapies. Novel interventions has been designed pilot tested for each of these factors to produce healing environment. The purpose of this study is to evaluate the effects of each individual factor and combination of all on the range …
- 0 views
- 19 Feb, 2024
A Study to Explore Personalized Treatment for Patients with Recurrent Gynecological Malignancies Based on MTB (RWS-MTB)
This analysis will examine the implementation and clinical efficacy of personalized targeted therapies guided by molecular tumor profiling and multidisciplinary consultation.The prospective arm will enroll 200 patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) referred for multidisciplinary consultation.
- 0 views
- 17 Jan, 2025
Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia
A better understanding of the therapeutic and neuromodulatory mechanisms of tDCS as an adjunct to language therapy in nfvPPA may have a significant impact on the development of effective therapies for PPA, and may offer insight into ways of impeding neurodegeneration that may improve patients' quality of life, as well …
- 0 views
- 19 Feb, 2024
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
Here both, radiotherapeutic (salvage radiotherapy of the lymphatic drainage) and surgical interventions (salvage lymph node dissection = removal of the pelvic lymph nodes) are offered on an individual basis. These regional therapies mainly aim to achieve a delay of further progression of the prostate cancer disease, and thus delay the …
- 0 views
- 19 Feb, 2024
Effectiveness and Acceptability of MINDFULNESS by Smartphone for Patients With Chronic Migraine and Medication Overuse
It has been also reported how the clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication.
- 0 views
- 19 Feb, 2024
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Eligibility Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options. Design Participants will be screened with: blood tests physical …
- 0 views
- 19 Feb, 2024
Neoadjuvant T-VEC in High Risk Early Melanoma
Survival remains significantly poorer for thicker and ulcerated lesions with T3b and T4 lesions demonstrating less than 50% survival at 5 years independent of other prognostic indicators. Oncolytic viral therapies (OVT) stimulate or suppress the immune system in different ways to stop cancer cells from growing and intra-lesional OVT has …
- 0 views
- 19 Feb, 2024
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …
- 0 views
- 19 Feb, 2024
Minocycline in MS: Confirmation of Benefit
This is an open-label, single-arm clinical trial. Trial participants will include men and women, aged 18-60 years who have had a first demyelinating event within the previous 180 days and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which are at least 3 mm …
- 0 views
- 19 Feb, 2024